| scholarly article | Q13442814 |
| P50 | author | Ann Richmond | Q63665124 |
| Kelli L. Boyd | Q116621330 | ||
| P2093 | author name string | Yan Liu | |
| Shawn Levy | |||
| Jeffrey A Sosman | |||
| Yu Shyr | |||
| Yingjun Su | |||
| Kimberly Brown Dahlman | |||
| Darrin D Stuart | |||
| Snjezana Zaja-Milatovic | |||
| Sarah P Short | |||
| Aixiang Jiang | |||
| Katayoun I Amiri | |||
| Mark C Kelley | |||
| Pengcheng Lu | |||
| Anna E Vilgelm | |||
| Oriana E Hawkins | |||
| Tammy Sobolik | |||
| Ryan C Splittgerber | |||
| Sara Kantrow | |||
| P2860 | cites work | The SLUG zinc-finger protein represses E-cadherin in breast cancer | Q24292674 |
| MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents | Q24297439 | ||
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 | ||
| Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction | Q24302447 | ||
| Clusterin inhibits apoptosis by interacting with activated Bax | Q24316499 | ||
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments | Q26863243 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors. | Q64880508 | ||
| Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin | Q78171998 | ||
| Nupr1: the Swiss-knife of cancer | Q84593468 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Factors underlying sensitivity of cancers to small-molecule kinase inhibitors | Q28252845 | ||
| Com-1/p8 acts as a putative tumour suppressor in prostate cancer | Q28266612 | ||
| Cancer genes and the pathways they control | Q28275089 | ||
| Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization | Q28287759 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia | Q33293905 | ||
| p8 is critical for tumour development induced by rasV12 mutated protein and E1A oncogene | Q33757514 | ||
| Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells | Q33759715 | ||
| Drosophila Cdk4 is required for normal growth and is dispensable for cell cycle progression | Q34488948 | ||
| Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS | Q34545490 | ||
| Use of DNA Microarray and Small Animal Positron Emission Tomography in Preclinical Drug Evaluation of RAF265, a Novel B-Raf/VEGFR-2 Inhibitor | Q34633685 | ||
| A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer | Q34760642 | ||
| Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration | Q36174662 | ||
| Loss of singleminded-2s in the mouse mammary gland induces an epithelial-mesenchymal transition associated with up-regulation of slug and matrix metalloprotease 2. | Q36498019 | ||
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 | ||
| Bcl-2-regulated apoptosis: mechanism and therapeutic potential | Q36880621 | ||
| Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic | Q36945203 | ||
| Regulation of membrane-type 4 matrix metalloproteinase by SLUG contributes to hypoxia-mediated metastasis | Q37478659 | ||
| New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances | Q37888981 | ||
| Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma | Q37902639 | ||
| Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244) | Q38300326 | ||
| Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells | Q38337454 | ||
| Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors. | Q39525856 | ||
| Protein Kinase D3 Sensitizes RAF Inhibitor RAF265 in Melanoma Cells by Preventing Reactivation of MAPK Signaling | Q39551441 | ||
| Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma | Q39732683 | ||
| Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors | Q39926451 | ||
| MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines | Q40066322 | ||
| Confirmation of a BRAF mutation-associated gene expression signature in melanoma. | Q40129786 | ||
| B-RAF is a therapeutic target in melanoma | Q40543086 | ||
| Microarray expression profiling in melanoma reveals a BRAF mutation signature. | Q40572664 | ||
| MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development | Q50640472 | ||
| Comparative genomics on SNAI1, SNAI2, and SNAI3 orthologs | Q53354668 | ||
| The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis | Q53450205 | ||
| Down-regulation of Platelet-Derived Growth Factor-D Inhibits Cell Growth and Angiogenesis through Inactivation of Notch-1 and Nuclear Factor-κB Signaling | Q56648795 | ||
| The CD44 standard/ezrin complex regulates Fas-mediated apoptosis in Jurkat cells | Q57357322 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2184-2198 | |
| P577 | publication date | 2012-02-20 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | RAF265 inhibits the growth of advanced human melanoma tumors | |
| P478 | volume | 18 |
| Q41311583 | A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status |
| Q36670740 | A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia |
| Q38091649 | Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring |
| Q35262625 | Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma |
| Q27006853 | Beyond BRAF: where next for melanoma therapy? |
| Q93133457 | Cell-type dependent enhancer binding of the EWS/ATF1 fusion gene in clear cell sarcomas |
| Q36359700 | Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. |
| Q36848064 | Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment |
| Q34646614 | Dabrafenib and its potential for the treatment of metastatic melanoma |
| Q64068495 | Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma |
| Q34639532 | Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies |
| Q42651903 | MDM2 Antagonists Counteract Drug-Induced DNA Damage. |
| Q27347800 | Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells |
| Q37450733 | Metastatic melanoma - a review of current and future drugs |
| Q35434188 | Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2. |
| Q37689575 | NRAS mutant melanoma: biological behavior and future strategies for therapeutic management |
| Q34978580 | Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma |
| Q38103961 | Phase I/II RAF kinase inhibitors in cancer therapy |
| Q39149843 | Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma |
| Q38885822 | Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma |
| Q50209952 | Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF (V600) mutation-positive solid tumors: a phase 1 study. |
| Q37038604 | Searching for the Chokehold of NRAS Mutant Melanoma. |
| Q41085432 | Small Molecules Antagonise the MIA-Fibronectin Interaction in Malignant Melanoma. |
| Q38585847 | Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. |
| Q38098888 | Targeting MAPK pathway in melanoma therapy |
| Q38124821 | Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma |
| Q36602188 | Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. |
| Q64055352 | Targeting the ERK Signaling Pathway in Melanoma |
| Q27687198 | Targeting the RAS oncogene |
| Q38620826 | The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy |
| Q38995628 | The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways. |
| Q38386344 | Treatment of NRAS-mutant melanoma. |
| Q33978378 | Understanding the biology of melanoma and therapeutic implications |
| Q28276886 | Vemurafenib: the first drug approved for BRAF-mutant cancer |
| Q26782585 | What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment |
Search more.